Meeting
2017 ASCO Quality Care Symposium
Potential drug-drug interaction events in patients treated with abiraterone acetate plus prednisone or enzalutamide.
Authors
Dominic Pilon
Groupe d'Analyse, Ltee, Montreal, QC, Canada
Dominic Pilon, Ajay S. Behl, Bruno Emond, Yongling Xiao, Patrick Lefebvre, Christopher J. Kane
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Patient Safety and Science of Quality
Track
Patient Safety,Science of Quality
Sub Track
Other
Citation
J Clin Oncol 35, 2017 (suppl 8S; abstract 44)
DOI
10.1200/JCO.2017.35.8_suppl.44
Abstract #
44
Poster Bd #
A12
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Drug-drug interactions in patients with castration-resistant prostate cancer undergoing abiraterone therapy: Characterizing the scale of the problem.
First Author: Rehana Jamani
Poster
2024 ASCO Genitourinary Cancers Symposium
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.
First Author: Charlotte Hawkins
Poster
2020 Genitourinary Cancers Symposium
Impact of upstream use of novel hormonal therapy on progression of patients (pts) to metastatic castration-resistant prostate cancer (mCRPC) in the United States (US).
First Author: Howard I. Scher
Poster
2019 Supportive Care in Oncology Symposium
Pharmacogenetic (PGx) guided cancer pain management in an oncology palliative medicine (PM) clinic.
First Author: Jai Narendra Patel